Development of new antibiotic combinations to be administered by dry powder for inhalation to patients with Cystic Fibrosis : microbiological, pharmacological and pharmaceutical studies
(2017)
Files
PhD_thesis_Hariri_Mustafa-Revision-final.pdf
Closed Access - Adobe PDF
- 12.28 MB
PhD_thesis_Hariri_Mustafa-Revision-finalpublic.pdf
Open Access - Adobe PDF
- 10.79 MB
Details
- Authors
- Supervisors
- Abstract
- This PhD thesis aimed at developing synergistic combinations of antibiotics in the form of dry powder for inhalation to be administered to patients with Cystic Fibrosis (CF). The combinations comprise of a macrolide, used in patients with CF for its anti-inflammatory effetcs, and an antibiotic active against Pseudomonas aeruginosa, the main pathogen causing chronic lung infection in patients with CF. The PhD thesis was divided into three different studies. First, microbiological study, examining antimicrobial resistance in CF population to different antipseudomonals and macrolides. Second, pharmacological study, focusing on the development of biofilm infection model relevant to CF pathophysiology and the activity of antibiotics alone or in combination in this model. Third, pharmaceutical study, involving the analytical and formulation development(laboratory and industrial scale) for the Tobramycin-Clarithromycin combination to be used as a dry powder for inhalation. This work highlights the importance of achieving high local concentrations of antibiotics in the lung and provides a candidate formulation for preclinical and clinical development of a combination of antibiotics for the treatment of chronic respiratory infection due to P. aeruginosa in patients with CF.
- Affiliations
Citations
Mustafa, M. H. (2017). Development of new antibiotic combinations to be administered by dry powder for inhalation to patients with Cystic Fibrosis : microbiological, pharmacological and pharmaceutical studies. https://hdl.handle.net/2078.5/48406